Stock LEXX LEXARIA BIOSCIENCE CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Real-time Estimate Cboe BZX
Other stock markets
 13:36:13 2024-05-14 EDT 		5-day change 1st Jan Change
3.135 USD -1.42% Intraday chart for Lexaria Bioscience Corp. -7.00% +155.20%
05-08 Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study CI
04-16 Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lexaria Begins Dosing of its Second GLP-1 Human Pilot Study
AQ
Lexaria Bioscience : Corporate Presentation
PU
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
AQ
Lexaria Bioscience : Corporate Highlight Sheet
PU
Lexaria Awarded New Patents
AQ
Lexaria Bioscience : Amendment of a Material Definitive Agreement - Form 8-K
PU
Lexaria to Present at The LD Micro Invitational XIV
NE
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
AQ
Lexaria Bioscience : Corporate Highlight Sheet
PU
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
AQ
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
AQ
7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study
AQ
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
AQ
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
AQ
Lexaria Submits Investigational New Drug Application
AQ
Lexaria Releases Annual Letter from the CEO
AQ
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
AQ
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
AQ
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
AQ
Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus-Branded GLP-1 drug Semaglutide
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LEXX Stock
  4. News Lexaria Bioscience Corp.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW